DS
PTCT icon

DRW Securities’s PTC Therapeutics PTCT Stock Holding History

DRW Securities’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-4,100
Closed -$249K – 124
2015
Q1 		$249K Buy
+4,100
New +$250K 0.04% 84

Other funds holding PTCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

DRW Securities's PTCT Position: Q1 2026 in Review

DRW Securities opened a new position in PTC Therapeutics (PTCT) in Q1 2026: 18,169 shares worth $1.24M. The stake represents 0.02% of the portfolio and ranks #286 among its holdings. This is a return to the name: DRW Securities previously reported a position in PTCT as recently as Q2 2025.

DRW Securities first reported a position in PTCT in Q2 2025 and has held it in 2 quarters since. 349 funds tracked by Wall St. Rank hold PTCT as of Q1 2026.

  • DRW Securities held 18,169 shares of PTC Therapeutics worth $1.24M as of Q1 2026.
  • PTC Therapeutics was a new DRW Securities position in Q1 2026.
  • PTC Therapeutics made up 0.02% of DRW Securities's portfolio in Q1 2026, its #286 holding.
  • DRW Securities first reported a position in PTC Therapeutics in Q2 2025 and has held it in 2 quarters since.
  • 349 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2026.

Based on DRW Securities's 13F filing for Q1 2026, filed 13 May 2026.